A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial

Autor: Stahel, Rolf, Peters, Solange, Soo, Ross, Han, Ji-Youn, Früh, Martin, Provencio, Mariano, Coate, Linda, Dafni, Urania, Hiltbrunner, Anita, Ruepp, Barbara, Roschitzki-Voser, Heidi, Gasca-Ruchti, Adriana, Giacomelli, Nino, Kammler, Rosita, Marti, Nesa, Nobs, Lionel, Pardo-Contreras, Mariana, Pfister, Rita, Piguet, Anne-Christine, Ribeli-Hofmann, Sabrina, Martinez, Virginia Rodriguez, Roux, Susanne, Sanchez-Hohl, Magdalena, Schneider, Mirjam, Schweri, Robin, Troesch, Sandra, Zigomo, Isabel, Tsourti, Zoi, Zygoura, Panagiota, Kassapian, Marie, Vervita, Katerina, Dimopoulou, Georgia, Andriakopoulou, Charitini, Fernandez, Maria, Pereira, Eva, Simona, Carolina, Tucker, Lisa, Burnes, Jillian, Barrett, Aisling, McGrillen, Meghan, Berset, Catherine, Biaggi, Christine, Reist, Martin, Rentsch, Priska, Cuffe, Sinead, Hashemi, Sayed, Nadal, Ernest, Carcereny, Enric, de Castro, Javier, Sala, Maria Angeles, Reyes, Bernabé, Pulla, Mariano Provencio, Campelo, Rosario Garcia, Massutí, Bartomeu, Garcia, Jose, Dómine, Manuel, Majem, Margarita, Sanchez, Jose Miguel, Britschgi, Christian, Pless, Miklos, Yeo, Chong Ming, Cho, Byoung Chul, Soo, R.A., Han, J.-Y., Dafni, U., Cho, B.C., Yeo, C.M., Nadal, E., Carcereny, E., de Castro, J., Sala, M.A., Bernabé, R., Coate, L., Provencio Pulla, M., Garcia Campelo, R., Cuffe, S., Hashemi, S.M.S., Früh, M., Massuti, B., Garcia-Sanchez, J., Dómine, M., Majem, M., Sanchez-Torres, J.-M., Britschgi, C., Pless, M., Dimopoulou, G., Roschitzki-Voser, H., Ruepp, B., Rosell, R., Stahel, R.A., Peters, S.

Publikováno v: In Annals of Oncology February 2022 33(2):181-192

Fulvestrant with or without selumetinib, a MEK 1/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: A multicentre randomised placebo-controlled double-blind phase II trial, SAKK 21/08

Autor: Zaman, Khalil, Winterhalder, Ralph, Mamot, Christoph, Hasler-Strub, Ursula, Rochlitz, Christoph, Mueller, Andreas, Berset, Catherine, Wiliders, Hans, Perey, Lucien, Rudolf, Christine Biaggi, Hawle, Hanne, Rondeau, Stephanie, Neven, Patrick

Publikováno v: In European Journal of Cancer July 2015 51(10):1212-1220

The ISG15 Isopeptidase UBP43 Is Regulated by Proteolysis via the SCFSkp2 Ubiquitin Ligase

Autor: Tokarz, Sara ^‡, Berset, Catherine ^§, La Rue, Janna ^{‡, ¶}, Friedman, Kevin ^{‡, ¶}, Nakayama, Kei-Ichi ^∥, Nakayama, Keiko ^∥, Zhang, Dong-Er ^**, Lanker, Stefan ^{‡, ‡‡}

Publikováno v: In Journal of Biological Chemistry 5 November 2004 279(45):46424-46430

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

SAKK 65/08: A Phase I Dose Escalation Study of Bortezomib in Combination with Nelfinavir in Patients with Advanced Hematologic Malignancies

Autor: Driessen, Christoph, Bader, Jürgen ^*, Kraus, Marianne ^*, Jörger, Markus ^*, Rosing, Hilde ^*, Berthod, Gregoire ^*, Hitz, Felicitas ^*, Berset, Catherine ^*, Xyrafas, Alexandros ^*, Hawle, Hanne ^*, Overkleeft, Hermann S ^*, Sessa, Christiana ^*, Huitema, Alwin ^*, Mey, Ulrich JM ^*, Pabst, Thomas, von Moos, Roger ^*, Hess, Dagmar ^*

Publikováno v: In Blood 6 December 2014 124(21):4747-4747